The use of ICT during COVID-19.

ICTs are pivotal in the existing social order and especially during the COVID-19 global pandemic. This panel focuses on the use of ICTs by different actors, including individuals, nonprofit organizations, and governments around the globe in responding to this COVID crisis. We tackle three essential questions about ICTs and the global crisis. First, what role do ICTs play in a global crisis? Second, how do ICTs affect social order when tensions between control, autonomy, and power shift? Third, what are the theoretical and practical implications of ICT use during a global health crisis? Each of the panelists will discuss their ongoing research in social informatics or health informatics as relates to the panel theme and central questions in order to provide a holistic view of the role of ICTs during this global pandemic.

Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.

Lung injury and fibrosis represent the most significant outcomes of severe and acute lung disorders, including COVID-19. However, there are still no effective drugs to treat lung injury and fibrosis. In this study, we report the generation of clinical-grade human embryonic stem cells (hESCs)-derived immunity- and matrix-regulatory cells (IMRCs) produced under good manufacturing practice requirements, that can treat lung injury and fibrosis in vivo. We generate IMRCs by sequentially differentiating hESCs with serum-free reagents. IMRCs possess a unique gene expression profile distinct from that of umbilical cord mesenchymal stem cells (UCMSCs), such as higher expression levels of proliferative, immunomodulatory and anti-fibrotic genes. Moreover, intravenous delivery of IMRCs inhibits both pulmonary inflammation and fibrosis in mouse models of lung injury, and significantly improves the survival rate of the recipient mice in a dose-dependent manner, likely through paracrine regulatory mechanisms. IMRCs are superior to both primary UCMSCs and the FDA-approved drug pirfenidone, with an excellent efficacy and safety profile in mice and monkeys. In light of public health crises involving pneumonia, acute lung injury and acute respiratory distress syndrome, our findings suggest that IMRCs are ready for clinical trials on lung disorders.